The High Court has declined a special leave application by Clive Palmer-owned mining firms challenging a judgment which ordered the billionaire to repay a $102 million loan taken out from Queensland Nickel prior to its collapse in 2016.
A judge has ordered that $1.27 million be set aside to cover the costs of the law firm administering the settlement in the class action over the federal government’s Robodebt scheme, cutting about $1 million from the figure sought.
A Melbourne law firm has lost its bid to delay payment of a $184,000 judgment to a former junior lawyer who earned hundreds of thousands of dollars per year under a lucrative pay structure.
WA Attorney-General John Quigley wants a second go at his trial testimony in a defamation case brought by mining magnate Clive Palmer, admitting he made “mistakes” while giving evidence in the witness box.
Wealth manager MLC Limited has admitted to violating the Corporations Act by failing to send overdue notices to policyholders over a 15-year period, but will defend the bulk of ASIC’s claims in proceedings accusing it of causing $17.5 million in harm to over a quarter of a million consumers.
Epic Games has argued in favour of steaming ahead with a trial in its competition case against Apple while its parallel case against Google remains in the embryonic stage, but the tech giants say Google’s litigation should catch up in the hopes that the court can hear a joint trial or hold contemporaneous hearings.
SingTel has been blocked from making $190,000 in tax deductions after the Australian Taxation Office won its Federal Court case against the Singaporean teleco over transfer pricing benefits related to the $14.2 billion acquisition of Optus.
Commenting on the unprecedented nature of the case against her client — the so-called postbox solicitor in the Banksia Securities class action — a senior barrister has told a court of her shock at the conduct of her former colleague at the bar, Norman O’Bryan, who acted as lead counsel in the scandal-ridden litigation.
A judge has questioned whether the lead applicant in a class action over sleep apnea machines with alleged safety defects was “appropriately resourced” to run the case against health tech giant Philips.
The ACCC has refused to authorise a patent settlement and license agreement between Bristol-Myers Squibb unit Celgene and two generic drug makers who sued to invalidate the patents for its blockbuster cancer drug Revlimid, saying it could distort competition between generic drug makers.